Harold Bernstein - 22 Sep 2025 Form 4 Insider Report for Maze Therapeutics, Inc. (MAZE)

Role
President, R&D & CMO
Signature
/s/ Courtney Phillips, as attorney-in-fact
Issuer symbol
MAZE
Transactions as of
22 Sep 2025
Net transactions value
$0
Form type
4
Filing time
24 Sep 2025, 16:24:14 UTC
Previous filing
30 Jan 2025
Next filing
31 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Bernstein Harold President, R&D & CMO C/O MAZE THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO /s/ Courtney Phillips, as attorney-in-fact 24 Sep 2025 0002050172

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MAZE Restricted Stock Units Award $0 +40,000 $0.000000 40,000 22 Sep 2025 Common Stock 40,000 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
F2 The award shall vest as to 1/2 of the total award on September 1, 2026 and September 1, 2027, subject to the reporting person's continued service to the Issuer on each vesting date.
F3 These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date.